by Haley Bridger
Mesenchymal stem cells (green) colonize a pancreatic islet in a preclinical model of diabetes. The blue dots represent the nuclei of cells within the islet. Credit: Robert Sackstein
Researchers at Harvard-affiliated Brigham and Women's Hospital (BWH) studying mesenchymal stem cells (MSCs)—a cell type useful in treating immune-related diseases—have uncovered a way to enhance and prolong the cells' therapeutic effects in a preclinical model of type 1 diabetes.
The research team, led by Harvard Medical School (HMS) Professor Robert Sackstein of BWH's Departments of Dermatology and of Medicine and HMS Associate Professor Reza Abdi of BWH's Department of Medicine and Transplantation Research Center, reports its results this week in the journal Stem Cells.
In type 1 diabetes, the body's immune cells obliterate pancreatic islets, where insulin is produced. MSCs are a type of adult stem cell with potent immune-suppressing and anti-inflammatory effects. In preclinical trials using diabetic-prone mice (non-obese diabetic mice), researchers had previously found that intravenous administration of MSCs could dampen pancreatic injury by reducing the levels of sugar in the mice's bloodstreams without insulin administration, but these effects were modest and temporary.
Sackstein and his team hypothesized that if more MSCs could be forced to populate inside the pancreatic islets, more islets could be spared from immune destruction, yielding a more complete reversal of diabetes.
MSCs normally lack a key cell surface adhesion molecule called HCELL, which mediates the homing of cells in the bloodstream to sites of tissue inflammation. The injection of MSCs directly into pancreatic islets is not feasible because the pancreas is fragile and releases highly toxic enzymes when manipulated. To get intravenously administered MSCs to the sites of the immune attack, the research team engineered the HCELL homing molecule to steer them toward the inflamed pancreatic islets.
The team found that administering HCELL-bearing MSCs into diabetic mice caused the MSCs to lodge in the islets. The result was durable normalization of blood sugar levels, eliminating the need for insulin administration—a sustained reversal of diabetes
Sackstein, co-corresponding author of the study, concluded that while further studies of the effects of MSCs are warranted, the preclinical study represents an important step in the potential use of mesenchymal stem cells in the treatment of type 1 diabetes and other immune-related diseases.
Explore further: Detection of enterovirus infection in pancreatic islets in patients newly diagnosed with type 1 diabetes
This story is published courtesy of the Harvard Gazette, Harvard University's official newspaper. For additional university news, visit Harvard.edu.
Medical Xpress on facebook
Related Stories
Detection of enterovirus infection in pancreatic islets in patients newly diagnosed with type 1 diabetes
Dec 16, 2014
Norwegian scientists with European partners have found evidence for the presence of enterovirus in pancreatic islets of type 1 diabetic patients. This provides evidence consistent with the theory that a low grade enteroviral ...
Conclusive evidence on role of circulating mesenchymal stem cells in organ injury
Aug 21, 2014
Mesenchymal stem cells (MSCs) are present in virtually every type of human tissue and may help in organ regeneration after injury. But the theory that MSCs are released from the bone marrow into the blood ...
Bone marrow stem cells show promise in stroke treatment
Apr 09, 2014
Stem cells culled from bone marrow may prove beneficial in stroke recovery, scientists at UC Irvine's Sue & Bill Gross Stem Cell Research Center have learned.
Study finds key to identifying, enriching mesenchymal stem cells
Jun 20, 2014
The Children's Medical Center Research Institute at UT Southwestern (CRI) has identified a biomarker that enables researchers to accurately characterize the properties and function of mesenchymal stem cells ...
New method yields potent, renewable human stem cells with promising therapeutic properties
Mar 25, 2014
The curative and therapeutic potential of mesenchymal stem cells (MSCs) offers much promise, as these multipotent cells are currently being tested in more than 300 clinical trials in a range of diseases. ...
Recommended for you
Blocking hormone could eliminate stress-induced infertility
3 hours ago
University of California, Berkeley, scientists have discovered that chronic stress activates a hormone that reduces fertility long after the stress has ended, and that blocking this hormone returns female ...
Scientists design nicotine vaccine that provokes robust immune response
14 hours ago
When a promising nicotine vaccine failed in clinical trials a few years ago, scientists from The Scripps Research Institute (TSRI) were determined to keep trying to help smokers overcome their addiction.
Researchers identify mechanism involved in causing cataracts in mice
14 hours ago
Cataract is one of the most common eye diseases, becoming more prevalent as people age. Over half of adults in the United States develop cataracts before age 80 and more than six million have undergone surgery ...
BPA and BPS affect embryonic brain development in zebrafish
14 hours ago
Bisphenol A, known as BPA, is produced in massive quantities around the world for use in consumer products, including household plastics. In response to public concerns, many manufacturers have replaced BPA ...
Sound mind, strong heart: Same protein sustains both
14 hours ago
A Roman philosopher was the first to note the relationship between a sound mind and a sound body. Now the findings of a new Johns Hopkins study reveal a possible biochemical explanation behind this ancient observation.
Researchers uncover more clues to how drug reverses obesity, diabetes, fatty liver disease
17 hours ago
Researchers at the University of Michigan have identified how a promising drug in clinical trials for the treatment of obesity and related metabolic disorders improves the metabolism of sugar by generating a new signal between ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
by Haley Bridger
Mesenchymal stem cells (green) colonize a pancreatic islet in a preclinical model of diabetes. The blue dots represent the nuclei of cells within the islet. Credit: Robert Sackstein
Researchers at Harvard-affiliated Brigham and Women's Hospital (BWH) studying mesenchymal stem cells (MSCs)—a cell type useful in treating immune-related diseases—have uncovered a way to enhance and prolong the cells' therapeutic effects in a preclinical model of type 1 diabetes.
The research team, led by Harvard Medical School (HMS) Professor Robert Sackstein of BWH's Departments of Dermatology and of Medicine and HMS Associate Professor Reza Abdi of BWH's Department of Medicine and Transplantation Research Center, reports its results this week in the journal Stem Cells.
In type 1 diabetes, the body's immune cells obliterate pancreatic islets, where insulin is produced. MSCs are a type of adult stem cell with potent immune-suppressing and anti-inflammatory effects. In preclinical trials using diabetic-prone mice (non-obese diabetic mice), researchers had previously found that intravenous administration of MSCs could dampen pancreatic injury by reducing the levels of sugar in the mice's bloodstreams without insulin administration, but these effects were modest and temporary.
Sackstein and his team hypothesized that if more MSCs could be forced to populate inside the pancreatic islets, more islets could be spared from immune destruction, yielding a more complete reversal of diabetes.
MSCs normally lack a key cell surface adhesion molecule called HCELL, which mediates the homing of cells in the bloodstream to sites of tissue inflammation. The injection of MSCs directly into pancreatic islets is not feasible because the pancreas is fragile and releases highly toxic enzymes when manipulated. To get intravenously administered MSCs to the sites of the immune attack, the research team engineered the HCELL homing molecule to steer them toward the inflamed pancreatic islets.
The team found that administering HCELL-bearing MSCs into diabetic mice caused the MSCs to lodge in the islets. The result was durable normalization of blood sugar levels, eliminating the need for insulin administration—a sustained reversal of diabetes
Sackstein, co-corresponding author of the study, concluded that while further studies of the effects of MSCs are warranted, the preclinical study represents an important step in the potential use of mesenchymal stem cells in the treatment of type 1 diabetes and other immune-related diseases.
Explore further: Detection of enterovirus infection in pancreatic islets in patients newly diagnosed with type 1 diabetes
This story is published courtesy of the Harvard Gazette, Harvard University's official newspaper. For additional university news, visit Harvard.edu.
Medical Xpress on facebook
Related Stories
Detection of enterovirus infection in pancreatic islets in patients newly diagnosed with type 1 diabetes
Dec 16, 2014
Norwegian scientists with European partners have found evidence for the presence of enterovirus in pancreatic islets of type 1 diabetic patients. This provides evidence consistent with the theory that a low grade enteroviral ...
Conclusive evidence on role of circulating mesenchymal stem cells in organ injury
Aug 21, 2014
Mesenchymal stem cells (MSCs) are present in virtually every type of human tissue and may help in organ regeneration after injury. But the theory that MSCs are released from the bone marrow into the blood ...
Bone marrow stem cells show promise in stroke treatment
Apr 09, 2014
Stem cells culled from bone marrow may prove beneficial in stroke recovery, scientists at UC Irvine's Sue & Bill Gross Stem Cell Research Center have learned.
Study finds key to identifying, enriching mesenchymal stem cells
Jun 20, 2014
The Children's Medical Center Research Institute at UT Southwestern (CRI) has identified a biomarker that enables researchers to accurately characterize the properties and function of mesenchymal stem cells ...
New method yields potent, renewable human stem cells with promising therapeutic properties
Mar 25, 2014
The curative and therapeutic potential of mesenchymal stem cells (MSCs) offers much promise, as these multipotent cells are currently being tested in more than 300 clinical trials in a range of diseases. ...
Recommended for you
Blocking hormone could eliminate stress-induced infertility
3 hours ago
University of California, Berkeley, scientists have discovered that chronic stress activates a hormone that reduces fertility long after the stress has ended, and that blocking this hormone returns female ...
Scientists design nicotine vaccine that provokes robust immune response
14 hours ago
When a promising nicotine vaccine failed in clinical trials a few years ago, scientists from The Scripps Research Institute (TSRI) were determined to keep trying to help smokers overcome their addiction.
Researchers identify mechanism involved in causing cataracts in mice
14 hours ago
Cataract is one of the most common eye diseases, becoming more prevalent as people age. Over half of adults in the United States develop cataracts before age 80 and more than six million have undergone surgery ...
BPA and BPS affect embryonic brain development in zebrafish
14 hours ago
Bisphenol A, known as BPA, is produced in massive quantities around the world for use in consumer products, including household plastics. In response to public concerns, many manufacturers have replaced BPA ...
Sound mind, strong heart: Same protein sustains both
14 hours ago
A Roman philosopher was the first to note the relationship between a sound mind and a sound body. Now the findings of a new Johns Hopkins study reveal a possible biochemical explanation behind this ancient observation.
Researchers uncover more clues to how drug reverses obesity, diabetes, fatty liver disease
17 hours ago
Researchers at the University of Michigan have identified how a promising drug in clinical trials for the treatment of obesity and related metabolic disorders improves the metabolism of sugar by generating a new signal between ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment